Q2 2025 Aquestive Therapeutics Inc Earnings Call Transcript
Key Points
- Aquestive Therapeutics Inc (AQST) is on track for the FDA review process and pre-commercial launch activities for Anaphylm, their epinephrine sublingual film.
- The company has submitted a 120-day safety update to the FDA with no new or consequential findings.
- Aquestive Therapeutics Inc (AQST) has secured meetings in Canada and the EU for international expansion of Anaphylm.
- The company has a robust clinical package for Anaphylm, including 10 independent studies with over 930 exposures and 350 subjects.
- Aquestive Therapeutics Inc (AQST) ended the last quarter with $60 million in cash, sufficient for the initial launch of Anaphylm.
- Aquestive Therapeutics Inc (AQST) faces significant barriers in market access due to payer tactics like delay tactics, NDC blocks, and prior authorization documentation.
- The company reported a net loss of $13.5 million for the second quarter of 2025, compared to a net loss of $2.7 million in the second quarter of 2024.
- Total revenues decreased to $10 million in the second quarter of 2025 from $20.1 million in the second quarter of 2024, primarily due to one-time recognition of deferred revenue in the prior year.
- Selling, general, and administrative expenses increased significantly, driven by higher commercial spending for pre-launch activities and regulatory fees.
- Aquestive Therapeutics Inc (AQST) will need additional funding to appropriately support the launch of Anaphylm beyond the initial phase.
Good day and hank you for standing by. Welcome to Aquestive Therapeutics second-quarter 2025 earnings conference call (Operator Instructions) Please be advised that today's conference is being recorded.
I'll like to hand the conference over to your first speaker today, Brian Korb. Please go ahead.
Thank you, operator. Good morning and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer. We are going to provide an overview of recent business developments and performance for the second quarter of 2025, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; and Sherry Korczynski, Chief Commercial Officer.
As a reminder, the company's remarks today correspond with the earnings release that was issued after the market closed yesterday. In addition, a recording of today's call will be made available on the Aquestive's website within the Investor section
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
